N4 Pharma (N4P)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

0.65p
   
  • Change Today:
    -0.025p
  • 52 Week High: 3.07
  • 52 Week Low: 0.60
  • Currency: UK Pounds
  • Shares Issued: 268.78m
  • Volume: 1,668,891
  • Market Cap: £1.75m

Deal with Barclays    Trade now with Barclays Stockbrokers

N4 Pharma upbeat on latest tumour suppression study data

By Josh White

Date: Friday 15 Jul 2022

LONDON (ShareCast) - (Sharecast News) - Specialist pharmaceutical developer N4 Pharma updated the market on its recent preclinical study with TNF alpha on Friday.
The AIM-traded firm had said on 13 June that the Medicines Discovery Catapult study showed "clear tumour suppression" with 10ug of the TNF-alpha loaded onto its 'Nuvec' delivery platform, which was a lower dose than used in the earlier studies.

It said that biochemical analysis of blood and tissue samples was now complete, with testing confirming that treatment with 10ug TNF-alpha loaded onto Nuvec resulted in an increase in circulating plasma TNF-alpha levels.

Analysis also indicated that tissues including the liver and the tumour cells may have been responsible for the transfection with the TNF plasmid and subsequent release of TNF-alpha into the circulation to suppress the tumour.

The company said the study provided further data to better understand the mechanism that produced the tumour suppression.

It said the data indicated the most appropriate use of Nuvec in the oncology field would likely be to combine it with one or more nucleic acids alongside a targeting ligand, to allow specific cancer cells to be targeted.

"We continue to make good progress in understanding how Nuvec can be used in the oncology space and this work, combined with the potential opening up of the siRNA market and the early data coming from UQ on their oral work, gives us a lot of material to further focus our route to commercial success," said chief executive officer Nigel Theobald.

"We will provide a further update of this along with our interim results."

At 1248 BST, shares in N4 Pharma were up 8.94% at 2.56p.

Reporting by Josh White at Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

N4 Pharma Market Data

Currency UK Pounds
Share Price 0.65p
Change Today -0.025p
% Change -3.70 %
52 Week High 3.07
52 Week Low 0.60
Volume 1,668,891
Shares Issued 268.78m
Market Cap £1.75m

N4 Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
8.47% above the market average8.47% above the market average8.47% above the market average8.47% above the market average8.47% above the market average
14.81% below the sector average14.81% below the sector average14.81% below the sector average14.81% below the sector average14.81% below the sector average
Value
8.47% above the market average8.47% above the market average8.47% above the market average8.47% above the market average8.47% above the market average
14.81% below the sector average14.81% below the sector average14.81% below the sector average14.81% below the sector average14.81% below the sector average
Income Not Available
Growth Not Available

N4 Pharma Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:20 1,428 @ 0.70p
16:20 344,883 @ 0.64p
16:14 160,623 @ 0.64p
15:46 1,000 @ 0.60p
15:40 700 @ 0.60p

N4 Pharma Key Personnel

CEO Nigel Theobald

Top of Page